Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.40 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.37 |
| ▸ | LGMN | Q99538 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519204 | 1.00 | SLC6A4 (0.40) | SLC6A4CCR4KCNA5SCN5AKCND2 | |
| SCHEMBL520117 | 1.00 | SLC6A4 (0.40) | SLC6A4CCR4KCNA5SCN5AKCND2 | |
| SCHEMBL3705069 | 0.93 | CCR4 (0.47) | SLC6A4CCR4KCNA5SCN5AKCND2 | |
| SCHEMBL10205069 | 0.93 | ALK (0.43) | DPP4EML4ALKPDE7ASUV39H2 | |
| SCHEMBL13177793 | 0.93 | DPP4 (0.40) | CCR4DPP4EML4ALKLGMN | |
| SCHEMBL10126749 | 0.88 | DPP4 (0.40) | DPP4EML4ALKLGMN | |
| SCHEMBL5406594 | 0.87 | DPP4 (0.46) | DPP4PDE7ASUV39H2NTSR1 | |
| SCHEMBL3345453 | 0.87 | NTSR1 (0.43) | DPP4ALKPDE7ASUV39H2LGMN | |
| SCHEMBL30682434 | 0.87 | NTSR1 (0.43) | DPP4ALKPDE7ASUV39H2LGMN | |
| SCHEMBL310068 | 0.87 | NTSR1 (0.43) | DPP4ALKPDE7ASUV39H2LGMN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SLC6A4 1699/4885CCR4 1913/4885KCNA5 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.